Navigation Links
Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
Date:1/6/2017

SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre "DA" Gros M.D. has joined the executive management team as President and Chief Operating Officer.  

"Neurocrine is very pleased to welcome Dr. Gros as our President and Chief Operating Officer as we move forward with our transformation into a commercial entity," said Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences. "DA's breadth of experience across all aspects of drug development and commercialization will be of critical importance as we enter this period of rapid growth. He will also be instrumental in executing on our long-range strategic plans. We are excited to have him join our team."

"Neurocrine is a remarkably innovative company, leading the development of novel therapeutics to address major unmet needs in neurological and endocrine disorders," said Dr. Gros. "I am very excited to join the company during this pivotal growth phase and look forward to contributing to Neurocrine's continued success."

Dr. Gros has extensive experience in developing and executing bio-pharmaceutical growth strategies. He joins Neurocrine from Alnylam Pharmaceuticals where he served as Senior Vice President, Chief Business Officer and was a member of the Management Board. His responsibilities included strategy, finance, business development, communications, investor relations, and shared services. Prior to Alnylam, as Executive Vice President and Chief Strategy Officer at Sanofi, where he was a member of the Executive Committee, Dr. Gros' responsibilities included corporate strategy, business development and licensing, mergers and acquisitions, alliance management, and structured investments, including the corporate venture fund which he re-launched. Before Sanofi, Dr. Gros held management positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company. Dr. Gros holds an M.D. from The Johns Hopkins University School of Medicine, an M.B.A. from Harvard Business School, and a B.A. from Dartmouth College.

Neurocrine also announced the grant of an inducement award to Dr. Gros pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. In connection with his employment by Neurocrine, Dr. Gros will be granted an inducement award consisting of a stock option to purchase 350,000 shares of Neurocrine common stock. The stock option will vest over a period of four years, with 25% vesting on the first anniversary of its grant date and the balance vesting each month over the remaining three years. This award is subject to the terms and conditions of Neurocrine's Inducement Plan. The award will be effective on February 1, 2017, which is the first day of the first calendar month following the commencement of Dr. Gros' employment with Neurocrine, and will have an exercise price equal to the closing price of Neurocrine's common stock on the NASDAQ Global Select Market on that date. The award was granted as an inducement material to Dr. Gros' employment pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals in diseases with high unmet medical needs through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two programs are elagolix, a gonadotropin-releasing hormone antagonist in Phase III development for women's health that is partnered with AbbVie Inc., and INGREZZATM, a vesicular monoamine transporter 2 inhibitor for which an NDA has been filed with the FDA for the treatment of tardive dyskinesia, and is in Phase II development for patients with Tourette syndrome. Neurocrine plans to commercialize INGREZZA in the United States upon approval of the NDA by the FDA. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, INGREZZA development and commercialization, the Company's R & D pipeline and the Company overall. Specifically, the risks and uncertainties the Company faces include risks that INGREZZA or the Company's other product candidates may not obtain regulatory approval or that the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may make adverse decisions regarding INGREZZA or the Company's other product candidates; risks that clinical development activities may not be completed on time or at all; risks that clinical development activities may be delayed for regulatory or other reasons, may not be successful, or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the Company's product candidates may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with the Company's dependence on third parties for development, manufacturing and marketing activities; risks that the Company's research programs will not identify pre-clinical candidates for further development;  risks that the Company will be unable to raise additional funding required to complete development of all of its product candidates; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and other risks described in the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2016. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-the-appointment-of-david-alexandre-gros-md-president-and-chief-operating-officer-300386844.html


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference
2. Neurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference
3. Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference
4. Neurocrine Biosciences Announces the Acceptance of Three Scientific Abstracts for Valbenazine (NBI-98854) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver April 2016
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2015 Results
6. Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
7. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
8. Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
9. Neurocrine Biosciences to Present at Credit Suisses 24th Annual Healthcare Conference
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results
11. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... (PRWEB) , ... October 10, 2019 , ... Smile Brands ... Glenn Misono in Natomas, California and opening of a new A+ location in Natomas. ... convenient locations across the Sacramento area. The group’s 14 general dentists and three specialists ...
(Date:10/9/2019)... PARK, N.Y. (PRWEB) , ... October 09, 2019 ... ... will present the nation’s only complete teaching of Yoga Science and AMI Meditation ... Science of Yoga, this comprehensive training, held October 22-26, 2019 at the ...
(Date:10/8/2019)... ... October 09, 2019 , ... “When Seconds Count: Reports From ... the realities of the HEMS world through telling the real stories of the EMS ... creation of published author Jay A. Humphrey, an EMS helicopter pilot. He has been ...
Breaking Medicine Technology:
(Date:10/15/2019)... ... October 15, 2019 , ... Labeling for ... Guidance , **An FDAnews Webinar**, Tuesday, October 29, 2019, 1:30-3:00 p.m. EDT, ... have on new drug applications and biologics license applications? , How will the ...
(Date:10/11/2019)... Calif. (PRWEB) , ... October 11, 2019 , ... Inland ... of Temecula, CA. The new location has incredible views of the Temecula Valley and ... On 2.5 acres, the new facility offers both private rooms as well as double ...
(Date:10/10/2019)... N.Y. (PRWEB) , ... October 10, 2019 , ... ... Sports Nutrition) Annual Conference, Nutrition 21 was excited to hear the significant results ... the significant blood flow impact of Nitrosigine®. The clinical study poster entitled “The ...
(Date:10/8/2019)... Jose, CA (PRWEB) , ... October 08, 2019 , ... ... with gum disease in San Jose, CA experience relief from this common and treatable ... possible in order to save adults from living with uncomfortable symptoms, including tender and ...
(Date:10/8/2019)... ... October 08, 2019 , ... Over the past three decades, ... standout in the sports restaurant category by providing a higher-quality product and experience than ... menu as well as a "RAISE A MUG FOR THE CAUSE" campaign in support ...
Breaking Medicine News(10 mins):